ADVANCED BLADDER-CANCER - THE NEED TO IDENTIFY NEW AGENTS IN THE POST-M-VAC (METHOTREXATE, VINBLASTINE, DOXORUBICIN AND CISPLATIN) WORLD

被引:63
作者
ROTH, BJ
BAJORIN, DF
机构
[1] INDIANA UNIV,MED CTR,CTR CANC,DEPT MED,DIV HEMATOL ONCOL,INDIANAPOLIS,IN
[2] CORNELL UNIV,MED CTR,DEPT MED,NEW YORK,NY 10021
[3] MEM SLOAN KETTERING CANC CTR,DEPT MED,DIV SOLID TUMOR ONCOL,GENITOURINARY ONCOL SERV,NEW YORK,NY 10021
关键词
BLADDER NEOPLASMS; DRUG THERAPY;
D O I
10.1016/S0022-5347(01)67598-0
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:894 / 900
页数:7
相关论文
共 88 条
[11]   PHASE-II STUDY OF TAXOL, MERBARONE, AND PIROXANTRONE IN STAGE-IV NON-SMALL-CELL LUNG-CANCER - THE EASTERN COOPERATIVE ONCOLOGY GROUP RESULTS [J].
CHANG, AY ;
KIM, K ;
GLICK, J ;
ANDERSON, T ;
KARP, D ;
JOHNSON, D .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :388-394
[12]  
CHITAMBAR CR, 1991, CANCER RES, V51, P6199
[13]   GALLIUM NITRATE IN ADVANCED BLADDER-CARCINOMA - SOUTHWEST ONCOLOGY GROUP-STUDY [J].
CRAWFORD, ED ;
SAIERS, JH ;
BAKER, LH ;
COSTANZI, JH ;
BUKOWSKI, RM .
UROLOGY, 1991, 38 (04) :355-357
[14]   ORAL PIRITREXIM, AND EFFECTIVE TREATMENT FOR METASTATIC UROTHELIAL CANCER [J].
DEWIT, R ;
KAYE, SB ;
ROBERTS, JT ;
STOTER, G ;
SCOTT, J ;
VERWEIJ, J .
BRITISH JOURNAL OF CANCER, 1993, 67 (02) :388-390
[15]  
DOGLIOTTI L, 1993, P AM SOC CLIN ONCOL, V12, P239
[16]  
DREYFUSS A, 1994, P AN M AM SOC CLIN, V13, P287
[17]   PHASE-II TRIAL OF VINBLASTINE, IFOSFAMIDE, AND GALLIUM COMBINATION CHEMOTHERAPY IN METASTATIC UROTHELIAL CARCINOMA [J].
EINHORN, LH ;
ROTH, BJ ;
ANSARI, R ;
DREICER, R ;
GONIN, R ;
LOEHRER, PJ .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (11) :2271-2276
[18]  
EINHORN LH, 1994, P AM SOC CLIN ONCOL, V13, P229
[19]  
ELIAS L, 1988, CANCER RES, V48, P4868
[20]   PHASE-I TRIAL OF PIRITREXIM CAPSULES USING PROLONGED, LOW-DOSE ORAL-ADMINISTRATION FOR THE TREATMENT OF ADVANCED MALIGNANCIES [J].
FEUN, LG ;
SAVARAJ, N ;
BENEDETTO, P ;
HANLON, J ;
SRIDHAR, KS ;
COLLIER, M ;
RICHMAN, S ;
LIAO, SH ;
CLENDENINN, NJ .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (01) :51-55